PE20151435A1 - Laquinimod para reducir el dano talamico en la esclerosis multiple - Google Patents
Laquinimod para reducir el dano talamico en la esclerosis multipleInfo
- Publication number
- PE20151435A1 PE20151435A1 PE2015000472A PE2015000472A PE20151435A1 PE 20151435 A1 PE20151435 A1 PE 20151435A1 PE 2015000472 A PE2015000472 A PE 2015000472A PE 2015000472 A PE2015000472 A PE 2015000472A PE 20151435 A1 PE20151435 A1 PE 20151435A1
- Authority
- PE
- Peru
- Prior art keywords
- laquinimod
- multiple sclerosis
- thalamic damage
- reduce
- damage
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004577 laquinimod Drugs 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 230000000542 thalamic effect Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151435A1 true PE20151435A1 (es) | 2015-10-15 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000472A PE20151435A1 (es) | 2012-10-12 | 2013-10-09 | Laquinimod para reducir el dano talamico en la esclerosis multiple |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (OSRAM) |
| EP (1) | EP2961406A4 (OSRAM) |
| JP (1) | JP2015533163A (OSRAM) |
| KR (1) | KR20150080509A (OSRAM) |
| CN (1) | CN105263325A (OSRAM) |
| AR (1) | AR092993A1 (OSRAM) |
| AU (2) | AU2013329348A1 (OSRAM) |
| BR (1) | BR112015007782A2 (OSRAM) |
| CA (1) | CA2884272A1 (OSRAM) |
| CL (2) | CL2015000732A1 (OSRAM) |
| EA (1) | EA201590726A1 (OSRAM) |
| HK (1) | HK1218865A1 (OSRAM) |
| IL (1) | IL237745A0 (OSRAM) |
| MX (1) | MX2015004564A (OSRAM) |
| PE (1) | PE20151435A1 (OSRAM) |
| SG (1) | SG11201501874TA (OSRAM) |
| TW (1) | TW201420101A (OSRAM) |
| WO (1) | WO2014058979A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140235670A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries, Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| HK1225972A1 (zh) * | 2013-12-20 | 2017-09-22 | Teva Pharmaceutical Industries Ltd. | 利用拉喹莫德来延缓亨廷顿氏病的进展 |
| SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| KR20190064583A (ko) * | 2016-09-13 | 2019-06-10 | 인테크린 테라퓨틱스, 아이엔씨. | Chs-131로 다발성 경화증의 치료 |
| SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076681A2 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| CA2657716A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Cholanic acid amides |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| EP2648732A4 (en) * | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| HK1199820A1 (en) * | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201420101A (zh) | 2014-06-01 |
| US20160296511A1 (en) | 2016-10-13 |
| WO2014058979A2 (en) | 2014-04-17 |
| US20140107154A1 (en) | 2014-04-17 |
| KR20150080509A (ko) | 2015-07-09 |
| WO2014058979A8 (en) | 2015-04-16 |
| AU2017203896A1 (en) | 2017-06-29 |
| MX2015004564A (es) | 2015-07-21 |
| EP2961406A4 (en) | 2017-01-04 |
| HK1218865A1 (zh) | 2017-03-17 |
| CA2884272A1 (en) | 2014-04-17 |
| EP2961406A2 (en) | 2016-01-06 |
| SG11201501874TA (en) | 2015-05-28 |
| BR112015007782A2 (pt) | 2017-07-04 |
| CN105263325A8 (zh) | 2017-07-14 |
| CL2015000732A1 (es) | 2015-08-07 |
| CL2016002873A1 (es) | 2017-04-17 |
| AR092993A1 (es) | 2015-05-13 |
| WO2014058979A3 (en) | 2015-08-20 |
| AU2013329348A1 (en) | 2015-05-28 |
| CN105263325A (zh) | 2016-01-20 |
| EA201590726A1 (ru) | 2015-10-30 |
| JP2015533163A (ja) | 2015-11-19 |
| IL237745A0 (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151435A1 (es) | Laquinimod para reducir el dano talamico en la esclerosis multiple | |
| UY4230Q (es) | Bocadillo retorcido para mascota | |
| CR20110398S (es) | Colchón | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| UY4211Q (es) | Pizarra para marcadores | |
| UY34280A (es) | Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa. | |
| CL2014003534A1 (es) | Metodo para reducir el riesgo de un evento cardiovascular en un sujeto en terapia con estatina. | |
| UY34537A (es) | Composiciones y métodos para anticuerpos que actúan sobre el factor p | |
| CL2014003515A1 (es) | Composición herbicida que tiene actividad herbicida mejorada. | |
| MX2015006325A (es) | Una formulacion estabilizada de pemetrexed. | |
| BR112016017402A2 (pt) | fusões anti-pcsk9~glp-1 e métodos para uso | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| MX373239B (es) | Mejoras en o con relacion a compuestos organicos. | |
| IN2014DN11078A (OSRAM) | ||
| UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. | |
| UY34038A (es) | Esteres aromaticos para composiciones agroquimicas. | |
| BR112014032501A2 (pt) | composto, e, composição farmacêutica. | |
| MY175703A (en) | Tablets with improved acceptance and good storage stability | |
| UY4242Q (es) | Mesa | |
| ES2571402T3 (es) | Producto mejorado para el cuidado de heridas | |
| UY34755A (es) | Agentes para el control de la glycaspis brimblecombei | |
| UY34035A (es) | Compuestos fungicidas relacionados con el 4,5-dihidroisoxazol. | |
| CR20130615S (es) | Contenedor | |
| FR2990870B1 (fr) | Autoinjecteur. | |
| UY4189Q (es) | Exhibidor para mostrador |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |